FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances

被引:13
作者
Bruijns B. [1 ]
Folkertsma L. [1 ]
Tiggelaar R. [2 ]
机构
[1] Salvitat BV, Colosseum 15, Enschede, 7521, PV
[2] NanoLab Cleanroom, Institute, University of Twente, Drienerlolaan 5, Enschede, 7500, AE
来源
Biosensors and Bioelectronics: X | 2022年 / 11卷
关键词
Isothermal amplification; Molecular test; POC; RT-PCR; SARS-CoV-2; detection;
D O I
10.1016/j.biosx.2022.100158
中图分类号
学科分类号
摘要
Since the start of the COVID-19 pandemic, 10 manufacturers of molecular tests for SARS-CoV-2 have received Emergency Use Authorizations from the U.S. Food and Drug Administration for point-of-care or over the counter use. In this review, the working principle of these tests is described as well as the relevant characteristics (e.g. time-to-result and specimen type). The analytical (e.g. analytical sensitivity) and clinical performance (positive and negative percent agreement) and useability characteristics (e.g. cost, reusability and throughput) of these tests are compared and critically reviewed. Also details for relevant respiratory multiplex assays of these 10 manufacturers are discussed. Critical review of scientific literature on these authorized tests revealed that for many of these tests publications are almost or completely absent, with the exception of two systems. The Xpert Xpress has been thoroughly investigated and good performance has been reported, whereas ID NOW is also well-represented in literature, but has relatively low sensitivity. © 2022 The Author(s)
引用
收藏
相关论文
共 133 条
  • [1] Abbott, ID NOW
  • [2] Abbott, ID NOW - there IS NO time like ID NOW
  • [3] Abbott, ID NOW COVID-19 sample type labeling update - technical brief April 2020
  • [4] Abbott Diagnostics Scarborough, ID NOW COVID-19 IFU
  • [5] Aupaix A., Lazarova E., Chemais M., A brief performance evaluation and literature review of Abbott ID Now COVID-19 rapid molecular-based test, Journal of Virological Methods, 298, (2021)
  • [6] Basu A., Zinger T., Inglima K., Woo K.M., Atie O., Yurasits L., Aguero-Rosenfeld M.E., Performance of abbott ID now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York city academic institution, Journal of Clinical Microbiology, 58, 8, (2020)
  • [7] Berke E.M., Newman L.M., Jemsby S., Hyde B., Bhalla N., Sheils N.E., Cangelosi G.A., Pooling in a pod: a strategy for COVID-19 testing to facilitate a safe return to school, Public Health Reports, 136, 6, (2021)
  • [8] BioMerieux, BioFire respiratory panel 2.1-EZ IFU
  • [9] Blackall D., Moreno R., Jin J., Plotinsky R., Dworkin R., Oethinger M., Performance characteristics of the roche diagnostics cobas Liat PCR system as a COVID-19 screening tool for hospital admissions in a regional health care delivery system, Journal of Clinical Microbiology, 59, 10, (2021)
  • [10] Broder K., Babiker A., Myers C., White T., Jones H., Cardella J., Kraft C.S., Test agreement between roche cobas 6800 and cepheid genexpert xpress sars-cov-2 assays at high cycle threshold ranges, Journal of Clinical Microbiology, 58, 8, (2020)